Citi downgraded Galapagos to Neutral from Buy with a EUR 41 price target. The commercial outlook for Jyseleca has deteriorated further and timelines for the company’s key pipeline assets are being delayed, the analyst tells investors in a research note. The firm says that with meaningful clinical datasets now not expected until 2025, it finds it difficult to defend a Buy thesis in the short term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GLPG: